These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9529261)

  • 1. Cholesterol reduction yields clinical benefit: impact of statin trials.
    Gould AL; Rossouw JE; Santanello NC; Heyse JF; Furberg CD
    Circulation; 1998 Mar; 97(10):946-52. PubMed ID: 9529261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
    Gould AL; Davies GM; Alemao E; Yin DD; Cook JR
    Clin Ther; 2007 May; 29(5):778-794. PubMed ID: 17697899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol reduction yields clinical benefit. A new look at old data.
    Gould AL; Rossouw JE; Santanello NC; Heyse JF; Furberg CD
    Circulation; 1995 Apr; 91(8):2274-82. PubMed ID: 7697857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    Jones PH
    Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
    Hebert PR; Gaziano JM; Chan KS; Hennekens CH
    JAMA; 1997 Jul 23-30; 278(4):313-21. PubMed ID: 9228438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins for primary prevention: at what coronary risk is safety assured?
    Jackson PR; Wallis EJ; Haq IU; Ramsay LE
    Br J Clin Pharmacol; 2001 Oct; 52(4):439-46. PubMed ID: 11678788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
    Robinson JG; Smith B; Maheshwari N; Schrott H
    J Am Coll Cardiol; 2005 Nov; 46(10):1855-62. PubMed ID: 16286171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting.
    Gotto AM; Grundy SM
    Circulation; 1999 Mar; 99(8):E1-7. PubMed ID: 10051310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol lowering and the reduction of CHD incidence and total mortality: results from a meta-analysis of randomized trials.
    Holme I
    Cardiovasc Drugs Ther; 1992 Apr; 6(2):101-2. PubMed ID: 1390319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive lipid-lowering therapy: a clinical imperative.
    Pedersen TR
    Eur Heart J; 1998 Oct; 19 Suppl M():M15-21. PubMed ID: 9821012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [All mortality by cause of death. The challenge of coronary prevention].
    Fernández-Cruz A
    Rev Esp Cardiol; 1998; 51 Suppl 6():23-9. PubMed ID: 10050141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projected coronary heart disease risk benefit with ezetimibe.
    Davies GM; Cook JR; Erbey J; Alemao E; Veltri EP
    Atherosclerosis; 2005 Apr; 179(2):375-8. PubMed ID: 15777556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The power of statins: aggressive lipid lowering.
    Stein EA
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III25-31. PubMed ID: 12708636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.